Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$23.90 USD
+0.37 (1.57%)
Updated Jul 23, 2024 01:56 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DNLI 23.90 +0.37(1.57%)
Will DNLI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Other News for DNLI
Denali Therapeutics management to meet with Oppenheimer
Denali Therapeutics management to meet with Oppenheimer
JPMorgan smid & large cap biotech analysts hold analyst/industry conference call
JPMorgan smid & large cap biotech analysts hold analyst/industry conference call
ALS therapy market seen increasing to nearly $1.3B by 2029